Trends in kinase drug discovery: targets, indications and inhibitor design https://t.co/HwLGn2v7f9 - a new review analysing the landscape of kinase inhibitors that have been approved or reached clinical trials indicates that ~30% of the kinome has been explored with drugs so far
Some updates! 🎆
The program for #RECOMB2021, featuring six distinguished keynote speakers, is now available!
https://t.co/fjXs6cwPfo
To maximize the opportunity for every member of the community to join #RECOMB2021, we will offer #free registration to the conference! ⬇️
Great insight into @cjder23’s path to discovery of mutant RAS “...I made the discovery which changed the course of my professional career.” @UNC @HHMINEWS @UCSF
Quite a week for targeting K-Ras (G12C) with the report from @Amgen on AMG510 showing “Clinical Evidence That KRAS Is Indeed Druggable” https://t.co/hRYNwE2Ndw. @UCSFCancer@UCSF@UCBerkeley @HHMINEWS
1/2
Two drugs known as PARP inhibitors, olaparib (Lynparza) and rucaparib (Rubraca), were recently approved to treat some men with metastatic #prostatecancer: https://t.co/NNRZnll5X0 #NCICancerCurrentsBlog#repost
🚨🚨🚨 UPDATE — At sunset last night, in a military-style assault, Border Patrol raided our humanitarian aid camp, chasing and arresting 30+ people who were receiving care and detaining all aid workers, whose phones were confiscated along w/ any video footage of the raid.
Join fellow trainees, collaborators, and friends in 70th birthday celebration for Frank McCormick @UCSF - Two days of RAS pathway science featuring a tremendous line up! https://t.co/3tOjRbvVHJ
“An internal Facebook study in 2016 found that 64% of the people who joined extremist groups on the platform did so because Facebook’s recommendations algorithms steered them there.” https://t.co/UldguA1zBF via @NYTimes
A good read from @UCSF last month that reminds us why DACA recipients belong in the US. @UofCAHealth.
Striking down DACA would eliminate thousands of health care workers, thwarting America’s pandemic... https://t.co/Deq1NMPxpo via @statnews
RAS-targeted therapies: is the undruggable drugged? https://t.co/YM47qzwhbZ A new review by @ShivaMalek, Amanda Moore and Scott Rosenberg @genentech and Frank McCormick @UCSF published today
Keith Yamamoto took months off during his PhD at Princeton in the 70s to protest the Vietnam War. Now he holds Professor, Vice Chancellor of Research, & Vice Dean of Medical School positions at UCSF. You can be a scientist and advocate for change simultaneously.
The AACR is outraged and saddened by the pervasive racism and social injustices toward African Americans in our country and all people of color around the world. Read our full statement: https://t.co/kEV76CKYcw
I'm very excited to share that my thesis work is finally published. It was an amazing journey through the world of RAS biology and learning about efforts by many to find new therapeutic strategies. Thank you to @SBLabUCSF for being an awesome mentor and all the folks at @UCSF!
Our paper on principles guiding the discovery of cancer synthetic lethals is out today in @NatureComms! Congrats to @spaceman_ku and lab folks involved as well as KRAS gurus Frank McCormick and Allan Balmain who helped! @UCSFCancer @UCSF_BioE @QBI_UCSF
https://t.co/JkTclTEakJ
Great collaboration with Nadja Makki from @UF characterizing scoliosis associated transcriptome and regulome.
Genomic characterization of the adolescent idiopathic scoliosis associated transcriptome and regulome https://t.co/PMONaYNnXo